A US lawyer based in Alabama has filed a lawsuit claiming payments of up to $170.0 million from Sandoz, the generics arm of Swiss drug major Novartis, on the basis that its Medicaid reimbusement prices in the state are too high. Jere Beasley argues that the firm has been overcharging the health care insurer for more than a decade. A lawyer for Sandoz retorted by saying that the firm had, in fact, saved the state millions of dollars by selling low-cost generic versions of popular drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze